CAR T cells designed with anti-Her2 DARPin or DARPins specific for Her2, epidermal growth factor receptor (EGFR), and epithelial cell adhesion molecule (EpCAM) showed potent tumor regression in preclinical models [92,93,94]. This evidence concerns the gene EGFR and neoplasm.